Comments*

 
  • Academy Events

  • Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM
    The New York Academy of Sciences

    Presented by the Biochemical Pharmacology Discussion Group

    Register Now

    Uncontrolled, chronic inflammation is now considered a major component of many widespread diseases, which are now well-recognized as 'inflammatory diseases.' These include arthritis, asthma, atherosclerosis and peripheral vascular disease, Alzheimer’s disease, periodontal disease and cancer. There is general agreement that inflammation is not likely to be the causative factor in these diseases, but that it plays a key role in disease progression, tissue dysfunction and ultimately organ failure. In recent years, evidence has emerged that resolution of inflammation is a biochemically active process driven by multiple chemical mediators. Elucidation of the biochemical pathways contributing to the resolution of inflammation has provided many new anti-inflammatory targets and an opportunity for resolution-based pharmacology for treatment and prevention of inflammatory diseases. This symposium reviews recent discoveries and advances in the field, and demonstrates how this work translates into new approaches and new pharmacology to treat old diseases.

    Call for Poster and Presentation Abstracts:
    Abstract submissions are invited for a poster session, and several abstracts will be selected for short 'Late-breaking abstract' presentations. For complete submission instructions, please send an e-mail to Inflammation@nyas.org with the words "Abstract Information" in the subject line. The deadline for abstract submission is September 26, 2014.

    *Networking reception to follow.

    Registration Pricing

    Member $30
    Student / Postdoc Member $15
    Nonmember (Academia) $65
    Nonmember (Corporate) $85
    Nonmember (Non-profit) $65
    Nonmember (Student / Postdoc / Resident / Fellow) $45


    The Biochemical Pharmacology Discussion Group is proudly supported by



    • Merck
    • WilmerHale

    Mission Partner support for the Frontiers of Science program provided by Pfizer

    EmailPrint